HER-2/neu Protein Expression in Breast Cancer Evaluated by Immunohistochemistry

pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long‐term follow‐up

1991 • 5,979 citations

Diseases of the Breast

1971 • 1,803 citations

Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment.

1998 • 1,086 citations

c-erbB-2 Expression and Response to Adjuvant Therapy in Women with Node-Positive Early Breast Cancer

1994 • 981 citations

The HER‐2/ neu Oncogene in Breast Cancer: Prognostic Factor, Predictive Factor, and Target for Therapy

1998 • 973 citations

Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group.

1992 • 855 citations

HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas.

1997 • 811 citations

erbB-2 and Response to Doxorubicin in Patients With Axillary Lymph Node-Positive, Hormone Receptor- Negative Breast Cancer

1998 • 667 citations

erbB-2, p53, and Efficacy of Adjuvant Therapy in Lymph Node-Positive Breast Cancer

1998 • 628 citations

Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of erbB-2 protein overexpression in primary breast cancer.

1990 • 602 citations

Expression of c-erbB-2 oncoprotein: a prognostic indicator in human breast cancer.

1989 • 592 citations

HER-2/neu oncogene protein and prognosis in breast cancer.

1989 • 579 citations

Clinical significance of HER-2/neu oncogene amplification in primary breast cancer. The South Australian Breast Cancer Study Group.

1993 • 517 citations

Sensitivity of HER-2/neu antibodies in archival tissue samples: potential source of error in immunohistochemical studies of oncogene expression.

1994 • 495 citations

Specificity of HercepTest in Determining HER-2/neu Status of Breast Cancers Using the United States Food and Drug Administration–Approved Scoring System

1999 • 468 citations

HER-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma.

1992 • 466 citations

HER-2/neu amplification predicts poor survival in node-positive breast cancer.

1990 • 456 citations

neu/erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer. Toronto Breast Cancer Study Group.

1998 • 435 citations

Her-2/neu expression in node-negative breast cancer: direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease.

1993 • 432 citations

c-erb B2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases.

1996 • 423 citations

Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer

1992 • 387 citations

The addition of Herceptin (humanized anti-HER2 antibody) to first-line chemotherapy for HER2-overexpressing metastatic breast cancer (HER2+ MBC) markedly increases anti-cancer activity: A randomized, multinational controlled phase II trial.

1998 • 366 citations

Association of C‐erbB‐2 protein over‐expression with high rate of cell proliferation, increased risk of visceral metastasis and poor long‐term survival in breast cancer

1991 • 354 citations

Prognostic and predictive value of c-erbB-2 overexpression in primary breast cancer, alone and in combination with other prognostic markers.

1998 • 336 citations

Prognostic significance of HER-2 oncoprotein expression in breast cancer: a 30-year follow-up.

1992 • 318 citations

Comparison of Fluorescence In Situ Hybridization and Immunohistochemistry for the Evaluation of HER-2/neu in Breast Cancer

1999 • 310 citations

Follow-up study of HER-2/neu amplification in primary breast cancer.

1991 • 268 citations

Correlation between c-erbB-2 amplification and risk of recurrent disease in node-negative breast cancer.

1991 • 267 citations

Prognostic significance of her‐2/neu expression in breast cancer and its relationship to other prognostic factors

1991 • 262 citations

ERBB2 amplification is associated with tamoxifen resistance in steroid-receptor positive breast cancer

1994 • 250 citations

The HER‐2/ neu Oncogene in Breast Cancer: Prognostic Factor, Predictive Factor, and Target for Therapy

1998 • 249 citations

c-erbB-2 oncoprotein expression in primary and advanced breast cancer

1991 • 245 citations

The long term prognostic significance of c-erbB-2 in primary breast cancer

1991 • 225 citations

Prognostic significance of HER-2/neu oncoprotein expression in node-positive breast cancer. The influence of the pattern of immunostaining and adjuvant therapy

1994 • 212 citations

Prognostic significance of c-erbB-2 and estrogen receptor status in human breast cancer.

1991 • 187 citations

The prognostic value of c-erbB2 in primary breast carcinomas: A study on 942 cases

1995 • 183 citations

The relationship between c-erbB-2 expression, S-phase fraction and prognosis in breast cancer

1991 • 134 citations

c-erbB-2 expression and benefit from adjuvant chemotherapy and radiotherapy of breast cancer

1995 • 133 citations

Optimization of immunohistochemical detection of ERBB2 in human breast cancer: Impact of fixation

1994 • 123 citations

c-erbB-2 amplification in node-negative human breast cancer.

1989 • 117 citations

HER-2/neu amplification and overexpression in primary human breast cancer is associated with early metastasis.

1992 • 117 citations

Analysis of c-erbB-2 expression in breast carcinomas with clinical follow-up.

1989 • 115 citations

Immunohistochemical detection ofHER2/neu in patients with axillary lymph node negative breast carcinoma. A study of epidemiologic risk factors, histologic features, and prognosis

1995 • 104 citations

Human breast cancer: prognostic significance of the c-erbB-2 oncoprotein compared with epidermal growth factor receptor, DNA ploidy, and conventional pathologic features.

1992 • 103 citations

C-erbB-2 immunostaining: problems with interpretation.

1994 • 99 citations

Prognostic value of c-erbB2 overexpression in axillary lymph node positive breast cancer. Results from a randomized adjuvant treatment protocol

1994 • 95 citations

Prognostic and predictive relevance of c-erbB-2 and ras expression in node positive and negative breast cancer.

1994 • 93 citations

Prognostic significance of c-erbB-2 expression in node negative breast cancer

1993 • 80 citations

Long‐term survival in breast cancer related to overexpression of the c‐erbB‐2 oncoprotein: An immunohistochemical study using monoclonal antibody NCL‐CB11

1991 • 76 citations

p53 and c-erbB-2 as markers of resistance to adjuvant chemotherapy in breast cancer.

1998 • 64 citations

Expression of neu protein, epidermal growth factor receptor, and transforming growth factor alpha in breast cancer. Correlation with clinicopathologic parameters.

1991 • 61 citations

C-erbb-2 oncoprotein expressionversus internal mammary lymph node metastases as additional prognostic factors in patients with axillary lymph node-positive breast cancer

1992 • 61 citations

Detection of c-erbB-2 activation in paraffin-embedded tissue by immunohistochemistry

1992 • 56 citations

The predictive power of semiquantitative immunohistochemical assessment of p53 and c-erb B-2 in lymph node-negative breast cancer

1996 • 54 citations

Analysis of cerbB2 expression using a panel of 6 commercially available antibodies

1994 • 53 citations

Association of c-erbB-2 expression and S-phase fraction in the prognosis of node positive breast cancer

1991 • 51 citations

Node-negative breast cancers with p53(-)/HER2-neu(-) status may identify women with very good prognosis.

1996 • 49 citations

Her2/neu overexpression is associated with treatment failure in women with high-risk stage II and stage IIIA breast cancer (>10 involved lymph nodes) treated with high-dose chemotherapy and autologous hematopoietic progenitor cell support following standard-dose adjuvant chemotherapy.

1996 • 47 citations

HER-2 breast assay, linked to Herceptin, wins FDA's okay.

1998 • 40 citations

Assessment of c-erbB-2 amplification by immunohistochemistry in paraffin-embedded breast cancer.

1993 • 21 citations

C-erbB-2 Oncogene Product Expression Depends on Tumour Type and is Related to Oestrogen Receptor and Lymph Node Status in Human Breast Carcinoma

1993 • 21 citations

Semiquantitative assessment of c-erbB-2 (HER-2) status in cytology specimens and tissue sections from breast carcinoma.

1999 • 20 citations

Multivariate analysis of prognostic factors in lymph node negative breast cancer

1998 • 19 citations

Cited By (0)

Loading...